BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34018607)

  • 1. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
    Sun L; Barter Z; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
    Sun L; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
    Sun L; Yagoda S; Du Y; von Moltke L
    Drug Des Devel Ther; 2019; 13():2941-2955. PubMed ID: 31686778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
    Sun L; von Moltke L; Rowland Yeo K
    Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):503-510. PubMed ID: 30921503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
    Monahan C; McCoy L; Powell J; Gums JG
    Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.